BridgeMD
INtravenous Contrast computed tomography versus native computed tomography in patients with acute Abdomen and impaired Renal functiOn (INCARO) – a multicentre, open-label, randomised controlled trial
EU CTIS ID: 2024-512084-31-00
What this study is testing
To assess superiority of the diagnostic strategy of acute abdomen using intravenous (IV) contrast CT versus native CT in patients with impaired renal function.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients requiring emergency abdominal or body CT with eGFR 15-45 ml/min/1.73 m2. The eGFR is calculated from the last available plasma creatinine value taken maximum 24 hours before randomisation.
You likely can't join if
- Age < 18 years
- Already randomised in the trial once
- Pregnancy
- eGFR < 15 or > 45 ml/min/1.73 m2
- Renal replacement therapy within 30 days
- CT with IV contrast less than 72 hours ago
See the full eligibility criteria
- Patients requiring emergency abdominal or body CT with eGFR 15-45 ml/min/1.73 m2. The eGFR is calculated from the last available plasma creatinine value taken maximum 24 hours before randomisation.
- Age < 18 years
- Already randomised in the trial once
- Pregnancy
- eGFR < 15 or > 45 ml/min/1.73 m2
- Renal replacement therapy within 30 days
- CT with IV contrast less than 72 hours ago
- Suspicion of vascular occlusion or dissection or bleeding (i.e. need for iv contrast)
- CT needed without iv contrast to detect or rule out ureteral stone
- IV contrast allergy
- No signed written informed consent
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.